Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health ...
Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on ...
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Novo Nordisk (NVO – Research Report), retaining the price target of ...
WASHINGTON (TND) — The Senate Committee on Health, Education, Labor and Pensions held a hearing on Tuesday to discuss popular ...